Entrada Therapeutics (TRDA) Income from Continuing Operations (2020 - 2026)

Entrada Therapeutics' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 39717000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 128.93% year-over-year to 39717000.0; the TTM figure through Mar 2026 stood at 166218000.0 (down 772.7% YoY), while the FY2025 annual figure was 143750000.0, down 319.18% from the prior year.
• Income from Continuing Operations was 39717000.0 for Q1 2026 at Entrada Therapeutics, down from 39196000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 54989000.0 in Q2 2024 to a low of 44180000.0 in Q3 2025.
• Historically, Income from Continuing Operations has averaged 12895705.88 across 5 years, with a median of 21671000.0 in 2022.
• The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations jumped 452.05% in 2024, then tumbled 3794.25% in 2025.
• A 5-year view of Income from Continuing Operations shows it stood at 24629000.0 in 2022, then surged by 61.59% to 9459000.0 in 2023, then soared by 111.22% to 1061000.0 in 2024, then sank by 3794.25% to 39196000.0 in 2025, then slipped by 1.33% to 39717000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 39717000.0 (Q1 2026), 39196000.0 (Q4 2025), and 44180000.0 (Q3 2025), per Business Quant data.